We design enzymatic targeted biosolutions that target the specific polysaccharide structures of a single bacterial species. This allows us to precisely modulate or eliminate the biofilm matrix, rebalancing the microbiome by exposing only the targeted bacteria to natural elimination.
In complex environments, bacteria shield themselves by expressing a structural layer of Extracellular Polysaccharides (EPS). Together with extracellular DNA and proteins, this constitutes the biofilm, a robust protection against external stressors.
This resilience often forces the use of harsh chemicals or mechanical friction, which act as blunt instruments that fail to distinguish between good and bad bacteria.
We use an AI-driven pipeline to identify and design enzymatic biosolutions. These enzymes act as molecular scissors, cutting the specific chemical bonds of the biofilm matrix.
Biofilms are the natural state of the skin microbiome, serving as a protective home for both healthy and harmful bacteria. Traditional broad-spectrum treatments often disrupt this delicate ecosystem, leading to dysbiosis, an imbalance associated with conditions like acne and atopic dermatitis.
We offer a targeted enzymatic approach. By selectively degrading the biofilm matrix of specific pathogens, we strip them of their fitness without harming the beneficial commensal bacteria that are essential for immune education and colonization resistance.
Acne is driven by virulent C. acnes strains (notably phylotypes IA1 IA2), whereas other phylotypes act as commensals essential for a healthy microbiome. The virulent strains secrete damaging factors like Hyaluronidase A and hide within a biofilm shelter. Our enzymes dissolve this shield, exposing the pathogens to natural cleansing while leaving beneficial strains intact.
Flare-ups in atopic dermatitis are often driven by Staphylococcus aureus biofilms that crowd out protective species. By selectively dismantling this pathogenic layer, we allow beneficial commensals to recolonize and restore the skin's natural defense network.
Healthy skin relies on colonization resistance, where beneficial commensals physically outcompete pathogens. Virulent biofilms disrupt this defense. Our biosolutions selectively strip these pathogenic shields, tipping the balance back to beneficial species that actively suppress virulence and dampen inflammation.
Our enzymatic platform drives the transition to a bio-based economy, solving complex biofilm challenges across high-growth sectors where traditional chemicals fall short.
Enhancing food security and processing. We provide safe, non-toxic, and biocompatible biocontrols and processing aids for environments where harsh conventional chemicals are prohibited.
Supporting the green transition. By utilizing biodegradable enzymatic biosolutions, we offer an eco-friendly alternative to broad-spectrum chemical eradication, drastically reducing environmental footprints.
Designed for complex micro-structures (biomanufacturing infrastructure, membranes, sensors) where mechanical scrubbing is impossible. Our enzymes penetrate where liquids flow to ensure system integrity.
Potentiate your existing industrial actives. We break the biofilm diffusion barrier to restore the efficacy of standard preservatives and treatments without requiring higher chemical loads.
A proprietary computational engine that designs candidate polysaccharide depolymerases for virtually any bacterial target, delivering exceptionally high hit rates.
The output proteins and their optimized biochemical properties constitute novel, patentable intellectual property, uniquely tailored to your specific industrial or cosmetic constraint.
We are not a traditional drug company; we are a rapid biocatalyst discovery engine. You provide the problematic bacterial strain; we deliver the optimized enzyme sequence in weeks.
Our proprietary platform is built upon years of pioneering academic research in phage-host interactions, deep learning, and enzyme annotation by our founding team.
Demonstrates the predictability of phage-host interactions at the subspecies level, proving our foundational ability to link specific depolymerase sequences to their exact structural targets.
Showcases the underlying AI architecture (combining LLMs and convolutional neural networks) that forms the academic genesis of our highly accurate functional domain identification.
Supported by
